A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg ELB245 given once daily for 12 weeks (8 + 4 weeks) versus placebo and versus 4mg tolterodine given once daily in patients with incontinent overactive bladder (OAB)

Trial Profile

A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg ELB245 given once daily for 12 weeks (8 + 4 weeks) versus placebo and versus 4mg tolterodine given once daily in patients with incontinent overactive bladder (OAB)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2013 New source identified and integrated (German Clinical Trials Register; DRKS00003997).
    • 07 Aug 2007 Status changed from recruiting to discontinued.
    • 06 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top